Can anti-IgE be used to treat allergy?

Abstract

A summary of the properties of CGP 51901 is shown in Table 3. On the basis of its binding to IgE and IgE-secreting cells and its activity in vitro and in vivo, CGP 51901 is expected to be able to decrease serum IgE by direct clearance of IgE and by reduction of the numbers and productivity of IgE-secreting cells. The end result of reduction of IgE in the circulation and on mast cells is expected to be the attenuation of IgE-mediated reactions and the improvement in allergy symptoms. The effective serum concentration of CGP 51901 is expected to be in the range 1-10 micrograms/ml. Because CGP 51901 is an antibody specific for IgE, it is expected to be highly selective in its activity. Because IgE does not appear to be essential and because CGP 51901 has been rigorously tested to confirm its non-anaphylactic nature, this treatment is not expected to have any adverse effects. Therefore, CGP 51901 is expected to be safe and to have a good probability of being effective when it is tested in human clinical trials.

The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.

“…CGP 51901 is composed of the variable heavy (H) and light (L) chain regions of TES-C21 linked to the human ␥1 and constant regions. It has been shown to have the same binding properties as its parent murine antibody (18) and in vitro studies have demonstrated that it does not bind to other immunoglobulin isotypes nor to other circulating cells (18).…”

“…CGP 51901 was developed from an antibody selected from a panel of murine antibodies generated against human IgE (18). The parent antibody (TES-C21) was shown to bind with high affinity to free IgE and IgE expressed on the surface of B cells but not to induce histamine release from IgE-bearing basophils (18).…”

“…CGP 51901 was developed from an antibody selected from a panel of murine antibodies generated against human IgE (18). The parent antibody (TES-C21) was shown to bind with high affinity to free IgE and IgE expressed on the surface of B cells but not to induce histamine release from IgE-bearing basophils (18). Preincubation of IgE with the parent antibody prevented its binding to both high and low affinity IgE receptors and TES-C21 has been shown not to bind to cells bearing IgE already bound to high or low affinity receptors.…”

“…It consists of the heavy and light chain variable regions of a parent murine antibody and the heavy and light chain constant regions of the human and ␥ 1 antibody isotypes (18). It binds to the lowand high-affinity receptor-binding portions of human IgE located in the C ⑀ 3 domain.…”

Synthetic IgE peptide vaccine for immunotherapy of allergy

“…Human basophil studies have shown that FcεRI expression is regulated by the level of free IgE, so that reduced levels of free IgE should lead to lower densities of FcεRI on basophils and mast cells and lowered sensitivities [19,38,39]. And, anti-IgE may lead to the down-regulation of IgE production by eliminating or down-regulating IgE-expressing B cells, perhaps by cross-linking membrane-bound IgE and causing apoptosis or anergy [37,40] or perhaps by complement-mediated and cell-mediated cytolysis [41]. It has been difficult to demonstrate reduction of IgE-producing B cells in the clinical trials with monoclonal antibodies, but other in vivo and in vitro experimental results are supportive of an anti-IgE-expressing B cell mechanism [18].…”